Class action by businesses in the complementary medicines industry

We successfully defended a class action against five individual officers of the Therapeutic Goods Administration (TGA) worth in excess of $150 million. The class action was brought by 169 businesses in the complementary medicines industry who alleged substantial losses following the suspension by the TGA of the manufacturing licence of Pan Pharmaceuticals and subsequent recall of products. The litigation raised issues concerning the conduct of representative proceedings and involved a complex factual matrix which necessitated a labour intensive forensic factual investigation and assessment. A court-ordered mediation extending over four days resulted in a settlement of the action. The settlement was approved by the Federal Court of Australia. There was no finding nor concession of any wrongdoing by our clients. The compensation paid to the represented class of applicants was provided by the Commonwealth of Australia, which was the first respondent in the proceedings.


Related Articles

INSURERS WIN ON AGGREGATION CLAUSE IN COVERAGE DISPUTE OVER CLASS ACTION

Legal Directions

Bank of Queensland Ltd v AIG Australia Ltd [2018] NSWSC 1689 Clients of a financial planner had been defrauded in a…

Continue reading

Liable, but without a more probable than not cause

Legal Directions

Weber v Greater Hume Shire Council [2019] NSWCA 74 Background The defendant (respondent on the appeal), Greater Hume Shire Council (Council),…

Continue reading

Implications of COVID-19 on Professional Indemnity Insurers

Legal Directions

In our article published on 30 April 2020, we canvassed some potential implications arising from the COVID-19 outbreak for D&O insurance.…

Continue reading